Harvard College

Biogen, Incorporated

Alfred L Goldberg

Olga Kandror

Walter C Fiers

Vito J Palombella

Thomas P Maniatis

Tatos Akopian

Eric J Rubin

Oliver Rando

Shenhav Cohen

Ravikiran M Raju

Isis C Kettelhut

K H Swamy

Meera Unnikrishnan

Chin H Chung

Lawrence P Casson

Stephen A Goff

The present invention provides a method for inducing glucose uptake in a muscle cell by inhibiting Trim32 protein in the cell and to a method for inducing glucose uptake in a muscle cell, by increasing the abundance of plakoglobin protein in the cell.

Methods for inducing glucose uptake

The technology described herein relates to treatments for tuberculosis which target the ClpP1P2 protease complex, including ClpC1. Further embodiments relate to assays and screens for modulators of the ClpP1P2 protease complex, including ClpC1.

[object Object]

Disclosed herein is a method for regulating the activity of NF-&kgr;B in an animal comprising contacting cells of the animal with certain proteasome inhibitors.

Proteasome regulation of NF-KB activity

Methods are disclosed which employ cold-shock proteins, such as Trigger Factor, to confer cold-tolerance to cells and to enhance viability of cells at temperatures at which the cells would not normally remain viable. Proteins having peptidyl-proline isomerase activity are also disclosed as being useful to confer cold-tolerance to cells. Cells which overexpress cold-shock proteins are useful in cell-based expression systems which are intended to express proteins at low temperatures.

Methods of improving viability of cells at low temperature

The ATP-ubiquitin-dependent process has been shown to be responsible for the excessive protein degradation which occurs in conditions or disease states in which there is severe loss of body mass and negative nitrogen balance has been identified and key constituents in the process identified. A method of inhibiting the accelerated or enhanced proteolysis, a method of identifying inhibitors of the process, multipain and the proteasome inhibitor are the subject of the claimed invention.

ATP-dependent protease and use of inhibitors for same in the treatment

This invention relates to combinations and methods for the treatment of malignant and non-malignant diseases. More particularly, this invention relates to combinations of natural or recombinant tumor necrosis factors ('TNF') and non-steroidal anti-inflammatory agents, such as indomethacin and ibuprofen, useful for the growth inhibition or killing of transformed cells. According to this invention, the non-steroidal anti-inflammatory agents are used to reduce or eliminate the toxic side effects of high doses of TNFs employed in the treatment of malignant and non-malignant neoplastic diseases. Advantageously, the combinations and methods of this invention allow the administration of higher doses of TNF than those tolerated in conventional treatment regimens based upon TNF alone.

Combinations of tumor necrosis factors and anti-inflammatory agents and

Hosts and methods for producing recombinant products in high yields

Proteases derived from E. coli, and a method for preparing a proteinaceous mixture having proteolytic activity.

Growing community of inventors

Brookline, MA, United States of America

Alfred L Goldberg